# Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants

> **NCT07443436** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 30 (estimated)

## Conditions studied

- Interstitial Lung Disease

## Interventions

- **DRUG:** Azithromycin 250 mg x3/week (3 tablets/week)
- **DRUG:** Prednisone 10 mg/day
- **DRUG:** Hydroxychloroquine 400 mg/day
- **DRUG:** Active Comparator: Standard of care

## Key facts

- **NCT ID:** NCT07443436
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07443436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07443436, "Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07443436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*